OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 116 filers reported holding OCULAR THERAPEUTIX INC in Q4 2022. The put-call ratio across all filers is 0.82 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $38 | -78.7% | 12,242 | -63.8% | 0.00% | -100.0% |
| Q1 2023 | $178 | -99.7% | 33,849 | +121.5% | 0.00% | +100.0% |
| Q3 2022 | $63,000 | +53.7% | 15,285 | +51.4% | 0.00% | – |
| Q2 2022 | $41,000 | -68.0% | 10,094 | -45.2% | 0.00% | -100.0% |
| Q4 2021 | $128,000 | -67.3% | 18,415 | -52.9% | 0.00% | -50.0% |
| Q3 2021 | $391,000 | +58.3% | 39,101 | +159.4% | 0.00% | +100.0% |
| Q1 2021 | $247,000 | +10.8% | 15,072 | +39.8% | 0.00% | 0.0% |
| Q4 2020 | $223,000 | -5.5% | 10,778 | -62.0% | 0.00% | -50.0% |
| Q2 2020 | $236,000 | +206.5% | 28,347 | +82.1% | 0.00% | +100.0% |
| Q1 2020 | $77,000 | +140.6% | 15,568 | +47.5% | 0.00% | – |
| Q3 2019 | $32,000 | -93.0% | 10,553 | -78.5% | 0.00% | -100.0% |
| Q1 2017 | $455,000 | +337.5% | 49,024 | +1884.0% | 0.00% | +300.0% |
| Q1 2015 | $104,000 | – | 2,471 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 5,618,861 | $116,310,000 | 100.00% |
| Opaleye Management Inc. | 6,510,000 | $134,758,000 | 17.60% |
| DELTEC ASSET MANAGEMENT LLC | 2,168,573 | $44,889,000 | 6.87% |
| Versant Venture Management, LLC | 1,465,384 | $30,333,000 | 3.15% |
| GREAT POINT PARTNERS LLC | 856,162 | $17,723,000 | 2.88% |
| Affinity Asset Advisors, LLC | 220,000 | $4,554,000 | 2.41% |
| Altium Capital Management LP | 303,174 | $6,276,000 | 2.34% |
| Endurant Capital Management LP | 290,465 | $6,013,000 | 2.17% |
| MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 50,396 | $1,043,000 | 1.17% |
| Lisanti Capital Growth, LLC | 366,040 | $7,577,000 | 1.05% |